Clinical trial · Observational
Minimally Invasive Treatments of the Thyroid
Multicenter International Prospective Analysis on Minimally Invasive Treatments of the Thyroid (MIPA- MITT) of of Micropapillary Thyroid Carcinoma
NCT06333587CI-TRIAL-00075453MIPA-MITTrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective cohort study to test Minimally Invasive Treatments of the Thyroid (MITT) as potential alternative to surgery in patients with Papillary Thyroid MicroCarcinoma (PTMC)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Papillary Thyroid Microcarcinoma | Thyroid Gland Papillary Microcarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| image-guided thermal ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- image-guided thermal ablation
- description
- image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma
- interventionNames
- Procedure: image-guided thermal ablation
Primary outcomes (1)
- measure
- The proportion of patients with major complications occurring within one month after the date of intervention
- timeFrame
- 1 month
- description
- Complications will be reported according to modified Society of Interventional Radiology (SIR) classification
Secondary outcomes (3)
- measure
- Percentage of patients with local recurrence at 10 years
- timeFrame
- 10 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \> 18years * Patients with diagnosis of papillary thyroid microcarcinoma, citologically proven, suitable for MITT. * Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. * Patients must be accessible for follow-up Exclusion Criteria: * Tumors \> 1 cm, other citological type, refusal of MITT, unsuitable for MITT, unmanageable coagulative disorders * Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study
References
Publications (0)
Data not yet available
No reference posted for this study.